Delving into the Latest Updates on Guangdong Hospital of Traditional Chinese Medicine with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Immune System Diseases

Congenital Disorders

Herbal medicine

Mesenchymal stem cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Immune System Diseases	2
Infectious Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Herbal medicine	3
Mesenchymal stem cell therapy	1

1. Conduct a large-sample, multicenter, superiority, double-blind, randomized controlled clinical trial to verify the efficacy of TJC in reducing the risk of cardiovascular and cerebrovascular events in patients with metabolic syndrome at high cardiovascular and cerebrovascular risk (HCR-MS).
2. Further construct an evaluation system for the long-term cardiovascular and cerebrovascular benefits of traditional Chinese medicine in regulating glucose and lipid metabolism through the evaluative study of the cardiovascular and cerebrovascular benefits of TJC.

Start Date01 May 2025

Sponsor / Collaborator

Guangdong Hospital of Traditional Chinese Medicine

[+1]

ITMCTR2025000514

/ SuspendedNot Applicable

Optimized Integrated Traditional Chinese and Western Medicine Protocol Research for Angina with Non-obstructive Coronary Arteries

Start Date01 Apr 2025

Sponsor / Collaborator

Guangdong Hospital of Traditional Chinese Medicine

100 Clinical Results associated with Guangdong Hospital of Traditional Chinese Medicine

Login to view more data

0 Patents (Medical) associated with Guangdong Hospital of Traditional Chinese Medicine

Login to view more data

400

Literatures (Medical) associated with Guangdong Hospital of Traditional Chinese Medicine

01 Jun 2025·Toxicology and Applied Pharmacology

Demethylzeylasteral inhibits osteosarcoma cell proliferation by regulating METTL17-mediated mitochondrial oxidative phosphorylation

Article

Author: Cao, Jingyu ; Wang, Chengbo ; Aziz, Faisal ; Zhu, Xiangzhan ; Wang, Zimeng ; Li, Ya ; Zhang, Haotian ; Li, Xianxiao ; Yang, Minglei ; He, Lihua

Osteosarcoma (OS) represents the most common primary bone malignancy, characterized by substantial disability and mortality, thereby underscoring the critical need for more effective therapeutic interventions to improve clinical outcomes. Demethylzeylasteral (DEM) is a bio-active compound has been reported for its anti-tumor properties through various mechanisms. Nonetheless, the specific effects of DEM on OS have yet to be fully elucidated. This study demonstrated that DEM significantly inhibited OS cell proliferation both in vitro and in vivo. Mechanistically, DEM impairs mitochondrial OXPHOS by targeting METTL17, a known regulator of mitochondrial translation, resulting in reduced ATP production. Subsequent investigations revealed that METTL17 knockdown exerts potent anti-tumor effects in OS, significantly suppressing both in vitro cell proliferation and in vivo xenograft tumor growth. Furthermore, METL17 overexpression significantly alleviated the inhibitory effects of DEM on cell proliferation, while restoring ATP production and oxygen consumption rates. These findings suggest that DEM impedes OS growth by inducing mitochondrial dysfunction through targeting METTL17, thereby highlighting a novel therapeutic strategy and potential molecular target for OS treatment.

01 May 2025·International Immunopharmacology

Efficacy of multi-cycle Efgartigimod in achieving minimal symptom expression in myasthenia gravis: A comparative multi-center study

Article

Author: Huang, Wen ; Zhang, Zhengxue ; Mo, Jinping ; Zhou, Jing ; Hong, Liang ; Zhou, Haihong ; Feng, Huiyu ; Zhou, Yanxia ; Zhao, Yuanqi ; Wang, Shuangqing ; Lin, Xiaowei ; Wu, Wei ; Zhao, Zhongyan ; Zhu, Xiaohuan ; Chen, Chao ; Chen, Jiaxin ; Gu, Mei

OBJECTIVESEfgartigimod has been approved as an effective and safe treatment for myasthenia gravis (MG). However, real-world experience on multi-cycle efgartigimod treatment and its comparison with Standard of Care (SoC) remain limited. This study aimed to evaluate minimal symptom expression (MSE) as the treatment goal and compared the proportion and time to achieving it between two groups.METHODSPatients receiving multi-cycle efgartigimod and contemporaneous counterparts treated with SoC were included. The rate of MSE achievement were compared using Kaplan-Meier analysis and Cox regression. Subgroup analysis focused on efgartigimod group, observing involved muscles and oral medication for further insights.RESULTSA total of 76 and 124 MG patients were enrolled in the efgartigimod and SoC groups, respectively. Efgartigimod group demonstrated a higher rate (73.3 % vs. 22.6 %, p < 0.001) and shorter time [0.7 (0.5, 3.1) vs. 3.3 (3, 6.1), months, p < 0.001] to achieving MSE compared to SoC group. Kaplan-Meier analysis revealed efgartigimod group had a higher MSE probability with a median time of 2.27 (95 %CI, 0.70, 4.39) months. MG Patients had a 9.69 fold (95 %CI, 5.54, 16.92) greater chance of achieving MSE compared to SoC group, remaining significant at 9.44 fold (95 %CI, 5.36, 16.60) after adjusting for ADL scores. After treatment, respiratory and bulbar symptoms improved significantly, with average scores from 0.57 ± 0.87 to zero, and 2.62 ± 2.56 to 0.37 ± 0.96. Additionally, the daily dosage of corticosteroid dropped from 20(10, 25) mg to 10(10,20) mg, with only 7 (9.2 %) patients requiring over 20 mg/day.CONCLUSIONMulti-cycle efgartigimod treatment achieves early MSE more effectively than SoC, serving as a fast-acting therapy for MG.

01 May 2025·Journal of Affective Disorders

Major depressive disorder and the development of cerebral small vessel disease: A Mendelian randomization study

Article

Author: Lu, Ting ; Xu, Yan ; Liao, Huijuan ; Cheng, Xiao ; Sun, Haiyang ; Sun, Jingbo ; Ren, Zhixuan ; Yu, Shiyao ; Yang, Jie ; Chen, Daiyi ; Luo, Lijun ; Zhao, Wen ; Li, Yueying

BACKGROUNDAlthough observational studies indicate a complex, bidirectional association between major depressive disorder (MDD) and cerebral small vessel disease (CSVD), the results are frequently inconsistent. This study investigated the potential correlation of MDD with both CSVD clinical outcomes and radiological markers, utilizing a bidirectional Mendelian randomization (MR) study design.METHODSInstrumental variables for MDD were obtained from the latest and largest genome-wide association study (GWAS). For CSVD, we extracted genetic instruments from GWAS datasets corresponding to both clinical outcomes and radiological markers, including intracerebral hemorrhage, small vessel ischemic stroke, white matter hyperintensities volume, mean diffusivity (MD), fractional anisotropy, brain microbleeds, and enlarged perivascular space (PVS). We employed the inverse variance weighting method as the primary analysis, complemented by conducting extensive sensitivity and heterogeneity tests.RESULTSIn the forward MR analyses, we discovered that the genetically predicted risk of MDD exhibits a potential causal relationship with two CSVD phenotypes demonstrating microscopic white matter (WM) damage: mean diffusivity (β = 0.784, 95 % CI 0.285-1.283, p = 0.002) and WM-PVS (OR = 1.053, 95%CI 1.010-1.097, p = 0.015). A single SNP (rs2232423) was identified as significantly influencing the causal relationship between MDD and WM. After excluding this SNP, our estimated association between MDD and increased MD (β = 0.516, 95%CI -0.001-1.033, p = 0.048) remained. The effects of MDD on WM-PVS passed all the tests for heterogeneity and pleiotropy. Reverse MR analyses showed no evidence of reverse causality between MDD and an altered CSVD risk.CONCLUSIONSThis study supports a potential causal association between MDD and CSVD-related indicators of impaired WM microstructure. These insights hold promise for improving risk assessment methods in CSVD.

100 Deals associated with Guangdong Hospital of Traditional Chinese Medicine

Login to view more data

100 Translational Medicine associated with Guangdong Hospital of Traditional Chinese Medicine

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

2

1

Phase 3 Clinical

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Zihua Wenfei Zhike Granules	Infectious Diseases More	Phase 3
PeiTu QingXin Granules	Dermatitis, Atopic More	Phase 2
Adipose-derived multipotent mesenchymal stem cells(Guangdong Hospital of Traditional Chinese Medicine)	Psoriasis More	Phase 2
QiShen Granules	Heart failure with normal ejection fraction More	Clinical
LN435a ( TGF-β1 )	Breast Cancer More	Pending